SGLT2 inhibitor ‘shows similar efficacy’ for men and women with HFrEF

Dapagliflozin reduces the risk of worsening heart failure and death similarly in both sexes in patients with heart failure with reduced ejection fraction (HFrEF), researchers say.
And symptoms, function, and quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) improved to similar degrees in men and women, they report in JAMA Cardiology.
In a prespecified secondary analysis of the DAPA-HF study, UK-led researchers analysed data from 4744 patients (23% women) randomised to guideline-recommended therapy plus once-daily 10mg dapagliflozin or placebo.
All participants were New York Heart Association (NYHA) functional class II to IV, with an ejection fraction of 40% or less and elevated N-terminal pro-B-type natriuretic peptide.